Treatment with RIPK1-specific inhibitors such as necrostatin-1 (Nec-1), GSK963 and 5-(3′,5 dimethoxybenzal)-2-thio-imidazole-4-ketone (DTIO) also reduced infarct volume and neurological deficit scores and significantly decreased ischemia-induced neuroinflammation and generation of reactive oxygen species (ROS) [15,25–27]. The gene discussed is RIPK1; the disease is ischemia.